Evidence map›Paper›PMID 34298972›Full record

ReviewInternational journal of molecular sciences2021

Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy.

Francesca Marini, Maria Luisa Brandi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Serums miR-24-3p and miR-1301-3p as Potential Biomarkers in MEN1 Syndrome.International journal of molecular sciences · 2025
    Article
  2. Review
  3. Article
  4. Menin in Cancer.Genes · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Senescent CD8Cancer science · 2023
    Article
  10. Rare Monogenic Diseases: Molecular Pathophysiology and Novel Therapies.International journal of molecular sciences · 2022
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Francesca MariniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.
Maria Luisa BrandiF.I.R.M.O., Italian Foundation for the Research on Bone Diseases, Via Reginaldo Giuliani 195/A, 50141 Florence, Italy.ORCID 0000-0002-8741-0592
Giuliani (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant inherited multiple cancer syndrome of neuroendocrine tissues. Tumors are caused by an inherited germinal heterozygote inactivating mutation of the

Indexed as

Genetic TherapyMolecular Targeted Therapy3' Untranslated RegionsAnimalsAntagomirsChromosomes, Human, Pair 19Chromosomes, Human, Pair 9DNA DamageFeedback, PhysiologicalForecastingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMicroRNAsMultiple Endocrine Neoplasia Type 1Neoplasm Proteins3' Untranslated RegionsAntagomirsMEN1 protein, humanMicroRNAsMIRN24 microRNA, humanNeoplasm ProteinsProtein IsoformsProto-Oncogene ProteinsRNA, MessengerRNA, Neoplasmloss of heterozygosity (LOH)MEN1 genemicroRNA (miRNAs)miR-24multiple endocrine neoplasia type 1 (MEN1)

Identifiers

PMID34298972
PMCPMC8306915
OpenAlexW3182387120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.